Report cover image

U.S. Central Nervous System Therapeutics Market Size, Share, Trends, & Industry Analysis Report, By Disease (Neurovascular Disease, CNS Trauma, Mental Health), By Drug Class, and By Distribution Channel– Market Forecast, 2025–2034

Published Jul 01, 2025
Length 129 Pages
SKU # PLRS20324339

Description

The U.S. central nervous system therapeutics market size is expected to reach USD 84.86 Billion by 2034, according to a new study by Polaris Market Research. The report “US Central Nervous System Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Disease (Neurovascular Disease, CNS Trauma, Mental Health), By Drug Class, By Distribution Channel – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Central Nervous System (CNS) therapeutics refers to treatments aimed at managing and alleviating disorders affecting the brain, spinal cord, and nerves, such as depression, epilepsy, Parkinson’s disease, and Alzheimer’s. These therapies include medications, biologics, and emerging digital and precision medicine approaches designed to improve neurological function and quality of life.

The integration of digital health and telemedicine is driving the growth. The US is leading the way in integrating digital health tools into the management of CNS disorders. The rapid rise of telemedicine more patients now have access to mental health consultations, therapy sessions, and medication management from their homes with rise in telemedicine. Mobile apps, wearable devices, and digital platforms are increasingly used to track symptoms, monitor adherence, and support behavioral therapy. For conditions such as depression, anxiety, and epilepsy, these tools provide real-time insights and enable personalized treatment plans. Additionally, insurers are beginning to reimburse digital treatments, encouraging wider adoption. Digital integration is becoming a key differentiator in the CNS therapeutics space with patients expecting convenience and real-time care. The combination of advanced technology, high smartphone usage, and a supportive regulatory environment drives the market.

The US Food and Drug Administration (FDA) plays a crucial role in accelerating the growth of the CNS therapeutics market through programs like Fast Track, Breakthrough Therapy, and Accelerated Approval. These initiatives are designed to speed up the review of drugs for serious CNS conditions with unmet medical needs, such as ALS, Alzheimer’s, and treatment-resistant depression. Recent high-profile drug approvals in the US demonstrate the country’s leadership in bringing innovative therapies to market quickly. Once approved, the large US healthcare system ensures swift commercial rollout, supported by robust pharmaceutical marketing and distribution channels. Patients further have relatively quick access to new drugs due to insurance coverage and patient assistance programs. This streamlined path from lab to patient encourages pharmaceutical companies to prioritize the US as their primary launch market. Consequently, the US continues to dominate global CNS drug commercialization and innovation, strengthening its market growth.

US Central Nervous System Therapeutics Market Report Highlights

The mental health segment accounted for 29.26% regional share during the forecast period driven by a surge in diagnosed cases of depression, anxiety, bipolar disorder, and PTSD.

The hospital pharmacy segment accounted USD 16.50 billion revenue in 2024 as hospital pharmacies are the leading distribution channel for CNS therapeutics in the country, particularly for acute and complex neurological conditions.

The global key market players are AstraZeneca plc; Biogen Inc.; Eli Lilly and Company; Johnson & Johnson; Merck & Co., Inc.; Neuraxpharm; Novartis AG; Otsuka Pharmaceutical Co., Ltd; Pfizer Inc.; Takeda Pharma Company Ltd; Teva Pharmaceutical Industries Ltd.

Polaris market research has segmented the US Central Nervous System Therapeutics Market report based on Disease, drug class, and distribution channel:

By Disease (Revenue - USD Billion, 2020–2034)

Neurovascular Diseases

CNS Trauma

Mental Health

Neurodegenerative Diseases

Alzheimer’s Disease

Parkinson's Disease

Multiple Sclerosis

Huntington’s Disease

Amyotrophic Lateral Sclerosis

Others

Infectious Diseases

CNS Cancer

Others

By Drug Class (Revenue - USD Billion, 2020–2034)

Anesthetics

Anticonvulsants

Antiemetic

CNS Stimulants

Pain Relievers

Others

By Distribution Channel (Revenue - USD Billion, 2020–2034)

Hospital Pharmacy

Retail Pharmacy

Other

Table of Contents

129 Pages
1. US Central Nervous System Therapeutics Market–Report Overview
1.1. Scope Of The Report
1.2. Market Segment Analysis
1.3. Regulatory Scenario By Region/Country
1.4. Market Investment Scenario Strategic
1.5. Market Analysis By Disease (USD Million)
2. US Central Nervous System Therapeutics Market Share By Disease (2025-2034)
2.1. Neurovascular Diseases
2.1.1. CNS Trauma
2.1.2. Mental Health
2.1.3. Neurodegenerative Diseases
2.1.3.1. Alzheimer’s Disease
2.1.3.2. Parkinson's Disease
2.1.3.3. Multiple Sclerosis
2.1.3.4. Huntington’s Disease
2.1.3.5. Amyotrophic Lateral Sclerosis
2.1.3.6. Others
2.2. Infectious Diseases
2.3. CNS Cancer
2.4. Others
3. US Central Nervous System Therapeutics Market Share By Drug ClassIn 2025 & 2034
3.1. Anesthetics
3.2. Anticonvulsants
3.3. Antiemetic
3.4. CNS Stimulants
3.5. Pain Relievers
3.6. Others
4. US Central Nervous System Therapeutics Market Share By Distribution Channel In 2025 & 2034
4.1. Us Central Nervous System Therapeutics Market Share By Distribution Channel (2025-2034)
4.2. Hospital Pharmacies
4.3. Retail Pharmacies
4.4. Others
5. Driver Restraint Challenge And Opportunities Of Central Nervous System Therapeutics Market
5.1. Driver, Restraint, Challenge And Opportunities Analysis
5.1.1. Market Driver Analysis
5.1.2. Market Restraint Analysis
5.1.3. Market Opportunity
5.1.4. Market Challenges
6. US Growth Trends
6.1. Industry Trends
6.1.1. SWOT Analysis
6.1.1.1. Strengths
6.1.1.2. Weaknesses
6.1.1.3. Opportunities
6.1.1.4. Threats
6.1.2. Pestel Analysis
6.1.2.1. Political Landscape
6.1.2.2. Economic Landscape
6.1.2.3. Social Landscape
6.1.2.4. Technological Landscape
6.1.2.5. Environmental Landscape
6.1.2.6. Legal Landscape
6.1.3. Porter’s Five Forces Analysis
6.1.3.1. Bargaining Power of Suppliers
6.1.3.2. Bargaining Power of Buyers
6.1.3.3. Threat Of Substitutes
6.1.3.4. Threat Of New Entrants
6.1.3.5. Competitive Rivalry
6.2. Potential Market And Growth Potential Analysis
6.2.1. Covid-19 Impact
6.2.1.1. Covid V, U, W And L Analysis
6.2.1.2. Covid V Analysis
6.2.1.3. Covid U Analysis
6.2.1.4. Covid L Analysis
6.2.1.5. Covid W Analysis
7. Companies Analysis
7.1. US Central Nervous System Therapeutics Market, Sales Area, Product Type
7.2. Mergers & Acquisitions, Partnerships, Product Launch, And Collaboration In Us Central Nervous System Therapeutics Market
7.3. Companies List
8. Executive Summary
8.1. US Central Nervous System Therapeutics Market Forecast, 2021-2034, (USD Million)
8.2. US Central Nervous System Therapeutics Market By Disease (2021-2034), (USD Million)
8.3. US Central Nervous System Therapeutics Market By Neurodegenerative Diseases (2021-2034), (USD Million)
8.4. US Central Nervous System Therapeutics Market By Drug Class (2021-2034), (USD Million)
8.5. US Central Nervous System Therapeutics Market By Distribution Channel (2021-2034), (USD Million)
9. Company Profiles
9.1. Biogen Inc.
9.1.1. Company Details
9.1.2. Financial (USD Million)
9.1.3. Product Summary
9.1.4. Recent Developments
9.2. Otsuka Pharmaceutical Co., Ltd.
9.2.1. Company Details
9.2.2. Financial (USD Million)
9.2.3. Product Summary
9.2.4. Recent Developments
9.3. Eli Lilly And Company.
9.3.1. Company Details
9.3.2. Financial (USD Million)
9.3.3. Product Summary
9.3.4. Recent Developments
9.4. Merck & Co., Inc.
9.4.1. Company Details
9.4.2. Financial (USD Million)
9.4.3. Product Summary
9.4.4. Recent Developments
9.5. AstraZeneca Plc.
9.5.1. Company Details
9.5.2. Financial (USD Million)
9.5.3. Product Summary
9.5.4. Recent Developments
9.6. Takeda Pharmaceutical Company.
9.6.1. Company Details
9.6.2. Financial (USD Million)
9.6.3. Product Summary
9.6.4. Recent Developments
9.7. Novartis AG.
9.7.1. Company Details
9.7.2. Financial (USD Million)
9.7.3. Product Summary
9.7.4. Recent Developments
9.8. Teva Pharmaceutical Industries Ltd.
9.8.1. Company Details
9.8.2. Financial (USD Million)
9.8.3. Product Summary
9.8.4. Recent Developments
9.9. Johnson & Johnson.
9.9.1. Company Details
9.9.2. Financial (USD Million)
9.9.3. Product Summary
9.9.4. Recent Developments
9.10. Pfizer Inc.
9.10.1. Company Details
9.10.2. Financial (USD Million)
9.10.3. Product Summary
9.10.4. Recent Developments
9.11. Neuraxpharm
9.11.1. Company Details
9.11.2. Financial (USD Million)
9.11.3. Product Summary
9.11.4. Recent Developments
10. Conclusion
11. Reference Link
12. Analyst Suggestions And Recommendations
13. Appendix
14. Methodology
14.1. Research Data Source
14.2. Secondary Data
14.2.1. Key Data From Secondary
14.3. Primary Data
14.3.1. Key Data From Primary
14.4. Industry Insight From Professional Leaders
14.5. Market Estimation
14.5.1. Market Estimation: Top-Down And Bottom-Up Approach
15. Legal Disclaimer
16. Research Scope
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.